These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 6147204)

  • 21. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.
    Daniel DG; Wozniak P; Mack RJ; McCarthy BG
    Psychopharmacol Bull; 1998; 34(1):61-9. PubMed ID: 9564200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The schizophrenia prodrome: a developmentally informed review and update for psychopharmacologic treatment.
    Thomas LE; Woods SW
    Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):109-33. PubMed ID: 16321727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Depot neuroleptics in social psychiatric practice].
    Pruss U; Rose HK; Zechner A
    Psychiatr Prax; 1984 Jul; 11(4):101-8. PubMed ID: 6148764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Structure, levels and deficiencies regarding the abilities of schizophrenics (author's transl)].
    Schelling U
    Fortschr Neurol Psychiatr Grenzgeb; 1980 May; 48(5):249-66. PubMed ID: 6104624
    [No Abstract]   [Full Text] [Related]  

  • 26. [4 years using clozapine in community psychiatry].
    Fremont P; Bazin N; Pillot B; Lochu A; Colen Demelo P; Pastol I; Zanata G
    Encephale; 1996 Dec; 22 Spec No 6():24-7. PubMed ID: 9102315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kraepelinian schizophrenia: a subgroup of schizophrenia?
    Keefe RS; Mohs RC; Davidson M; Losonczy MF; Silverman JM; Lesser JC; Horvath TB; Davis KL
    Psychopharmacol Bull; 1988; 24(1):56-61. PubMed ID: 2898796
    [No Abstract]   [Full Text] [Related]  

  • 28. Psychopharmacologic issues in the maintenance treatment of schizophrenia.
    Kane JM; Borenstein M; Woerner M
    Psychopharmacol Bull; 1984; 20(3):423-5. PubMed ID: 6147875
    [No Abstract]   [Full Text] [Related]  

  • 29. The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics.
    Spohn HE; Coyne L
    Brain Cogn; 1993 Sep; 23(1):28-39. PubMed ID: 8105820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.
    Revicki DA
    J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment.
    Cohen D; Dekker JJ; Peen J; Gispen-de Wied CC
    Eur Neuropsychopharmacol; 2006 Apr; 16(3):187-94. PubMed ID: 16263247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics.
    Tan YL; Zhou DF; Cao LY; Zou YZ; Zhang XY
    Neurosci Lett; 2005 Jul 1-8; 382(1-2):27-32. PubMed ID: 15911116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new hope for schizophrenics: efficacy of a new drug.
    Marimuthu C; Prashanth ; Prabhakaran K
    Nurs J India; 1996 Jul; 87(7):149-51. PubMed ID: 8998043
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
    Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
    Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein D is associated with long-term outcome in patients with schizophrenia.
    Hansen T; Hemmingsen RP; Wang AG; Olsen L; Timm S; Søeby K; Jakobsen KD; Fenger M; Parnas J; Rasmussen HB; Werge T
    Pharmacogenomics J; 2006; 6(2):120-5. PubMed ID: 16402085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormalities in 5-HT2A receptor mRNA expression in frontal cortex of chronic elderly schizophrenics with varying histories of neuroleptic treatment.
    Hernandez I; Sokolov BP
    J Neurosci Res; 2000 Jan; 59(2):218-25. PubMed ID: 10650880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of indocyanine green in the assessment of liver function in schizophrenics].
    Badurski J; Makosa M; Sarosiek J; Tolwiński T
    Pol Tyg Lek; 1973 Jan; 28(4):118-20. PubMed ID: 4405675
    [No Abstract]   [Full Text] [Related]  

  • 38. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.
    Lieberman JA
    J Clin Psychiatry; 1996; 57 Suppl 11():68-71. PubMed ID: 8941173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Statistical investigation in long term hospitalized schizophrenics].
    Mohs U
    Nervenarzt; 1966 Jan; 37(1):34-6. PubMed ID: 5963997
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug-behavior therapy outcomes with chronic schizophrenics.
    Liberman RP; Wiegand W
    J Clin Psychopharmacol; 1986 Feb; 6(1):52-3. PubMed ID: 2869061
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.